ACERUS OTC Stock Buy Hold or Sell Recommendation


USD 1.33  0.52  28.11%   

Assuming the 90 days horizon and complete risk avoidance on your part, our recommendation regarding ACERUS PHARMACEUTICALS CORP is 'Strong Sell'. Macroaxis provides ACERUS PHARMACEUTICALS buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ASPCF positions. The advice algorithm takes into account all of ACERUS PHARMACEUTICALS's available fundamental, technical, and predictive indicators you will find on this site.
The advice is provided from ACERUS PHARMACEUTICALS's buy-and-hold perspective. Please continue to ACERUS PHARMACEUTICALS Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as ACERUS and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards ACERUS PHARMACEUTICALS CORP.


The ACERUS recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on ACERUS PHARMACEUTICALS CORP. Macroaxis does not own or have any residual interests in ACERUS PHARMACEUTICALS CORP or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute ACERUS PHARMACEUTICALS's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Strong Sell



Hype Condition


Current Valuation


Odds of Distress


Economic Sensitivity


Analyst Consensus

Not Available

Reporting Quality (M-Score)

For the selected time horizon ACERUS PHARMACEUTICALS CORP has a Mean Deviation of 2.42, Standard Deviation of 8.68 and Variance of 75.37
We provide trade advice to complement the prevailing expert consensus on ACERUS PHARMACEUTICALS. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at this time. To make sure ACERUS PHARMACEUTICALS is not overpriced, please confirm all ACERUS PHARMACEUTICALS fundamentals, including its shares owned by insiders, ebitda, current ratio, as well as the relationship between the price to sales and cash per share . Given that ACERUS PHARMACEUTICALS is a hitting penny stock territory we recommend to closely look at its shares owned by institutions.

ACERUS PHARMACEUTICALS Trading Alerts and Improvement Suggestions

ACERUS PHARMACEUTICALS generated a negative expected return over the last 90 days
ACERUS PHARMACEUTICALS has high historical volatility and very poor performance
ACERUS PHARMACEUTICALS may become a speculative penny stock
ACERUS PHARMACEUTICALS has high likelihood to experience some financial distress in the next 2 years
The company has accumulated 40.36 M in total debt with debt to equity ratio (D/E) of 2.61, implying the company greatly relies on financing operations through barrowing. ACERUS PHARMACEUTICALS has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist ACERUS PHARMACEUTICALS until it has trouble settling it off, either with new capital or with free cash flow. So, ACERUS PHARMACEUTICALS's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ACERUS PHARMACEUTICALS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ACERUS to invest in growth at high rates of return. When we think about ACERUS PHARMACEUTICALS's use of debt, we should always consider it together with cash and equity.
The entity reported the revenue of 2.85 M. Net Loss for the year was (28.81 M) with profit before overhead, payroll, taxes, and interest of 1000 K.
ACERUS PHARMACEUTICALS CORP has accumulated about 1.29 M in cash with (22.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17.
Roughly 91.0% of ACERUS PHARMACEUTICALS shares are held by company insiders

ACERUS PHARMACEUTICALS Returns Distribution Density

The distribution of ACERUS PHARMACEUTICALS's historical returns is an attempt to chart the uncertainty of ACERUS PHARMACEUTICALS's future price movements. The chart of the probability distribution of ACERUS PHARMACEUTICALS stock daily returns describes the distribution of returns around its average expected value. We use ACERUS PHARMACEUTICALS CORP price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of ACERUS PHARMACEUTICALS returns is essential to provide solid investment advice for ACERUS PHARMACEUTICALS.
Mean Return0.14Value At Risk0.00
Potential Upside1.81Standard Deviation8.68
   Return Density   
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of ACERUS PHARMACEUTICALS historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.


Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ACERUS PHARMACEUTICALS or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ACERUS PHARMACEUTICALS's price will be affected by overall otc stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ACERUS otc's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Alpha over DOW
Beta against DOW-0.57
Overall volatility
Information ratio 0.0249


ACERUS PHARMACEUTICALS CORP is displaying above-average volatility over the selected time horizon. Investors should scrutinize ACERUS PHARMACEUTICALS CORP independently to ensure intended market timing strategies are aligned with expectations about ACERUS PHARMACEUTICALS volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure ACERUS PHARMACEUTICALS's otc stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact ACERUS PHARMACEUTICALS's otc stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.


Comparing ACERUS PHARMACEUTICALS's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ACERUS PHARMACEUTICALS's direct or indirect competition across all of the common fundamentals between ACERUS PHARMACEUTICALS and the related equities. This way, we can detect undervalued stocks with similar characteristics as ACERUS PHARMACEUTICALS or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of ACERUS PHARMACEUTICALS's fundamental indicators could also be used in its relative valuation, which is a method of valuing ACERUS PHARMACEUTICALS by comparing valuation metrics with those of similar companies.
 Better Than Average     
 Worse Than Average Compare ACERUS PHARMACEUTICALS to competition
Return On Asset(57.03) %(0.14) %
Operating Margin(891.63) %(5.51) %
Current Valuation53.33 M16.62 B
Shares Outstanding7.71 M571.82 M
Shares Owned by Insiders91.41 %10.09 %
Shares Owned by Institutions0.01 %39.21 %
Price to Book995.24 X9.51 X
Price to Sales5.01 X11.42 X
Revenue2.85 M9.43 B
Gross Profit1000 K27.38 B
EBITDA(25.21 M)3.9 B
Net Income(28.81 M)570.98 M
Cash and Equivalents1.29 M2.7 B
Cash per Share0.17 X5.01 X
Total Debt40.36 M5.32 B
Debt to Equity2.61 %48.70 %
Current Ratio0.37 X2.16 X
Book Value Per Share(1.52) X1.93 K
Cash Flow from Operations(22.47 M)971.22 M
Earnings Per Share(3.63) X3.12 X
Number of Employees1418.84 K
Market Capitalization14.3 M19.03 B


Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as ACERUS . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.


When is the right time to buy or sell ACERUS PHARMACEUTICALS CORP? Buying financial instruments such as ACERUS OTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having ACERUS PHARMACEUTICALS in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Manufacturing Thematic Idea Now

Manufacturing Theme
Companies that provide goods across residential, commercial and industrial construction such as machinery, tools, or lumber production. The Manufacturing theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Manufacturing Theme or any other thematic opportunities.
View All  Next Launch
Please continue to ACERUS PHARMACEUTICALS Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the ACERUS PHARMACEUTICALS information on this page should be used as a complementary analysis to other ACERUS PHARMACEUTICALS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for ACERUS OTC Stock analysis

When running ACERUS PHARMACEUTICALS price analysis, check to measure ACERUS PHARMACEUTICALS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACERUS PHARMACEUTICALS is operating at the current time. Most of ACERUS PHARMACEUTICALS's value examination focuses on studying past and present price action to predict the probability of ACERUS PHARMACEUTICALS's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ACERUS PHARMACEUTICALS's price. Additionally, you may evaluate how the addition of ACERUS PHARMACEUTICALS to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Is ACERUS PHARMACEUTICALS's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACERUS PHARMACEUTICALS. If investors know ACERUS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACERUS PHARMACEUTICALS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ACERUS PHARMACEUTICALS is measured differently than its book value, which is the value of ACERUS that is recorded on the company's balance sheet. Investors also form their own opinion of ACERUS PHARMACEUTICALS's value that differs from its market value or its book value, called intrinsic value, which is ACERUS PHARMACEUTICALS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACERUS PHARMACEUTICALS's market value can be influenced by many factors that don't directly affect ACERUS PHARMACEUTICALS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACERUS PHARMACEUTICALS's value and its price as these two are different measures arrived at by different means. Investors typically determine ACERUS PHARMACEUTICALS value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACERUS PHARMACEUTICALS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.